Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV

summarizeSummary

Moderna's 2025 annual report shows a significant revenue decline and a major pipeline setback with the CMV vaccine, but also highlights an improved net loss, key pipeline advancements, and new financing.

check_boxKey Events

• Significant Revenue Decline

  Total revenue decreased 40% to $1.9 billion in 2025, primarily due to lower sales volumes of COVID vaccines across all regions.

• Reduced Net Loss

  Net loss improved to $2.8 billion in 2025 from $3.6 billion in 2024, reflecting ongoing cost management and efficiency initiatives.

• CMV Vaccine Program Discontinued for Congenital CMV

  The Phase 3 study for the CMV vaccine candidate (mRNA-1647) in women of childbearing age failed its primary clinical endpoint, leading to the discontinuation of the program in this indication.

• Positive Oncology Pipeline Data

  Five-year data from the Phase 2b study of intismeran autogene (mRNA-4157) in combination with KEYTRUDA demonstrated sustained improvement in recurrence-free survival in high-risk melanoma patients.

auto_awesomeAnalysis

Moderna's 2025 annual report reveals a substantial 40% drop in total revenue to $1.9 billion, primarily driven by decreased COVID vaccine sales. While the company reduced its net loss to $2.8 billion, it also announced the discontinuation of its CMV vaccine program for congenital CMV after a Phase 3 failure. Despite these setbacks, Moderna made progress in its pipeline, including positive 5-year data for its individualized neoantigen therapy (mRNA-4157) and FDA acceptance of its amended BLA for the seasonal flu vaccine (mRNA-1010). The company also secured a $1.5 billion credit facility to enhance financial flexibility and continues to expand its global manufacturing footprint. Investors should monitor the company's ability to diversify its revenue streams beyond COVID vaccines, the progress of its oncology and rare disease pipeline, and the outcomes of ongoing extensive patent litigation.